Therapy News and Research

RSS

Concentric Medical announces treatment of first stroke patient with Merci Retriever

Concentric Medical, Inc., the global leader in devices for clot removal in acute ischemic stroke patients, today announced the treatment of the first patient in Japan with the Merci Retriever. The Merci Retriever is a catheter-based medical device that stroke centers use to remove blood clots from the brains of patients suffering an acute ischemic stroke.

21 Jul 2010

Health Canada grants Osiris Priority Review for Prochymal NDS

Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.

21 Jul 2010

Clinical research updates on interventional cardiology techniques that affect patient care

TCT 2010 will provide significant clinical research updates to technologies and practices in interventional cardiology that will directly affect patient care.

21 Jul 2010

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

AiCuris announced today publication of preclinical data on AIC246, at the International Herpesvirus Workshop in Salt Lake City, Utah, USA from 24 – 29 July 2010. AIC246 is a novel anti-HCMV drug currently in clinical phase 2 testing.

21 Jul 2010

ATLIS 2010 shows gap in patient-physician dialogue that may negatively impact patients' quality of life

Results from the landmark AIDS Treatment for Life International Survey, a multi-country survey of more than 2,000 people living with HIV/AIDS, revealed a significant gap in patient-physician dialogue about critical health-related conditions that may negatively impact patients' overall long-term health, quality of life, and treatment outcomes.

21 Jul 2010

Experts urge global leaders to commit $20 billion to Global Fund to Fight AIDS, Tuberculosis and Malaria

Scientists, practitioners and advocates from around the world today made a united call for global leaders to commit at least $US20 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria at its upcoming replenishment meeting in October. Because the level of replenishment committed at the meeting will determine the Global Fund's grant levels for 2011-2013, the meeting is widely viewed as the critical next step towards universal access to HIV prevention, treatment, care and support.

21 Jul 2010

Researchers block central pathway for prostate cancer progression

Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens.

21 Jul 2010

Vanderbilt University Medical Center performs specialized PET/CT scan to locate cancerous tumors

Vanderbilt University Medical Center and affiliated VA Tennessee Valley Healthcare System are the first in the U.S. to perform a specialized PET/CT scan to successfully locate the presence of tumors.

21 Jul 2010

Depressive symptoms in patients with HCV infection overlooked

Researchers from Denmark, Sweden, Norway and Finland (the NORDynamIC project group) have observed that depressive symptoms in patients with hepatitis C virus (HCV) infection are commonly overlooked in routine clinical interviews, and that treatment-induced depression compromises the outcome of HCV therapy. A second U.S. study found that patients with chronic infection had lower (work) productivity and incurred higher medical benefit costs than those without HCV.

21 Jul 2010

Scientists identify key genes for Silk Road disease

Scientists have identified key genes responsible for a severe inflammatory disease that has spread along the old silk trading routes from the Far East to the edge of Europe.University of Manchester researchers, working as part of a large international consortium, have revealed some of the genetic mutations that lead to Behçet's disease. The group's findings are published in Nature Genetics.

21 Jul 2010

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

Researchers from the La Jolla Institute for Allergy & Immunology have joined forces with the Dana-Farber Cancer Institute in Boston and Washington University in St. Louis to investigate a potential new therapy for sickle cell disease, a severe and chronic illness affecting more than 70,000 Americans and several million people worldwide.

21 Jul 2010

AIDS 2010: Number of HIV positive patients on arvs grew to 5.2m in 2009 with 10m still in need, who says

"The number of HIV-positive people receiving antiretroviral drugs [ARVs] for their infections jumped by more than a quarter in 2009, growing from 4 million to 5.2 million, the World Health Organization said Monday at the International AIDS Conference in Vienna," the Los Angeles Times reports (7/19).

21 Jul 2010

Scientists find way to block androgens, halt tumor progression in prostate cancer

Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens. Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor's growth.

21 Jul 2010

Eli Lilly completes Alnara acquisition

Eli Lilly and Company today announced that it has completed the acquisition of Alnara Pharmaceuticals, Inc., a privately-held company developing protein therapeutics for the treatment of metabolic diseases. The transaction, first announced on July 2, 2010, has received the approval of Alnara stockholders and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. All other closing conditions have also been met.

21 Jul 2010

Over-expression of Arpc1b promotes tumorigenic properties of breast cancer cells: Research

A major discovery, led by researchers from The George Washington University Medical Center, promises to revolutionize the way scientists think about key aspects of cellular lifecycle and offers a new avenue for cancer researchers to explore in their quest to one day slow down the progression of cancer.

21 Jul 2010

Hybrid Linac-MR imaging system tracks cancer tumors in real time

Today, at the 52nd Annual Meeting of the American Association of Physicists in Medicine (AAPM) in Philadelphia, a group of researchers from Stanford University will describe the latest developments toward their goal of integrating two existing medical devices -- medical linear accelerators, or "linacs," which produce powerful X-rays for treating cancer, and magnetic resonance imagers (MRIs), which are widely used to image tumors in the human body.

21 Jul 2010

CHLA receives $410,000 grant for 'first in childhood leukemia' multi-site study

J. Eric Bubbers, PhD, of the Saban Research Institute at Childrens Hospital Los Angeles, has received a $410,000 grant from Phase One Foundation. The award will fund a "first in childhood leukemia" multi-site study in children with relapsed or refractory acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML). Dr. Bubbers is the administrative director of Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), an academic research consortium consisting of 33 member institutions in four countries.

21 Jul 2010

GCSF administration can reduce side effects of cancer neurobastoma in children

Children given a hormone growth factor alongside chemotherapy for the aggressive cancer neuroblastoma are less likely to suffer a potentially deadly side-effect, according to a major international study published today (Tuesday) in the Journal of Clinical Oncology.

21 Jul 2010

FDA accepts MannKind's resubmission of AFREZZA NDA, sets PDUFA action date

MannKind Corporation today announced that it has submitted, and the U.S. Food and Drug Administration has accepted, MannKind's resubmission of its New Drug Application for AFREZZA™ (insulin human [rDNA origin]) and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act action date of December 29, 2010.

21 Jul 2010

International Stem Cell, IBVI sign letter of intent concerning funding, establishment of ISCO India

International Stem Cell Corporation, www.internationalstemcell.com, and Insight Bioventures India Private Limited, announced today that they have signed a letter of intent concerning funding and establishment of an Indian affiliate of ISCO. The goal is to establish world-class development and manufacturing operations for ISCO's research and pharmaceutical products in India, including its Lifeline Cell Technology research products and human corneal tissue, CytoCor, for treatment of corneal vision impairment and testing of chemicals.

20 Jul 2010

Therapy News and Research

Concentric Medical announces treatment of first stroke patient with Merci Retriever

Health Canada grants Osiris Priority Review for Prochymal NDS

Clinical research updates on interventional cardiology techniques that affect patient care

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

ATLIS 2010 shows gap in patient-physician dialogue that may negatively impact patients' quality of life

Experts urge global leaders to commit $20 billion to Global Fund to Fight AIDS, Tuberculosis and Malaria

Researchers block central pathway for prostate cancer progression

Vanderbilt University Medical Center performs specialized PET/CT scan to locate cancerous tumors

Depressive symptoms in patients with HCV infection overlooked

Scientists identify key genes for Silk Road disease

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

AIDS 2010: Number of HIV positive patients on arvs grew to 5.2m in 2009 with 10m still in need, who says

Scientists find way to block androgens, halt tumor progression in prostate cancer

Eli Lilly completes Alnara acquisition

Over-expression of Arpc1b promotes tumorigenic properties of breast cancer cells: Research

Hybrid Linac-MR imaging system tracks cancer tumors in real time

CHLA receives $410,000 grant for 'first in childhood leukemia' multi-site study

GCSF administration can reduce side effects of cancer neurobastoma in children

FDA accepts MannKind's resubmission of AFREZZA NDA, sets PDUFA action date

International Stem Cell, IBVI sign letter of intent concerning funding, establishment of ISCO India

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News